Navigation Links
Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
Date:6/1/2011

SINGAPORE, June 1, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that additional data from multiple Phase 1 and 2 clinical studies of its novel JAK2 inhibitor SB1518 further confirmed safety and efficacy for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. In the studies, SB1518 alleviated MF-associated splenomegaly and showed no evidence of myelosuppression and no exacerbation of cytopenias. Results will be presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago and the 16th Congress of the European Hematology Association (EHA) in London.

"Data pooled from the two Phase 1 trials demonstrate sustained clinical benefit in MF patients when treated with SB1518," said John Seymour, Head of the Department of Haematology at the Peter MacCallum Cancer Centre, Melbourne, "The once-daily dosing was well tolerated for over 2 years in on-going patients with no long-term toxicities observed."

Ruben A. Mesa, M.D., principal investigator at Mayo Clinic, said, "The new data from the Phase 2 study clearly showed durable responses in both spleen volume reduction and in relieving MF related symptoms. More importantly, these treatment effects were observed in MF patients with significantly impaired hematopoiesis without further exacerbating cytopenias. These results show that treatment with SB1518 is particularly important for MF patients with impaired hematopoiesis. The side effects were generally low grade, easily manageable and there were no discontinuations due to GI toxicities."

Dr. Jan-Anders Karlsson, CEO of S*BIO, added, "The data are further evidence that SB1518 is safe, effective and well tolerated in MF patients including those who present with severe splenomegaly.  The convenient once daily dose was well tolerated with manageable side effects across all studies. In light of these positive and encouraging results, we are rapidly advancing our JAK2 inhibitor through lat
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
2. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
3. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
4. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
5. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
6. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
7. Rosetta Genomics Announces Issuance of Additional U.S. Patent
8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
9. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
10. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
11. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Reported at American Association for Cancer Research ... -- Favrille,Inc. , a biopharmaceutical company developing ... announced,results from a new study showing enhanced ... key component in the Company's,Id/KLH immunotherapy product ...
... Origin May Be Useful in Cancer Treatment,Decisions , ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today ... might be used to,determine the original location of ... the annual meeting of the American Association,for Cancer ...
Cached Medicine Technology:Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 2Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 3Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma 4Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... teenagers have a lot in common: Sugary soda. Fast-food ... Low-income teenagers are almost three times more likely to ... to new research from the UCLA Center for Health ... 21 percent of teenagers living in low-income families are ...
... Calif., Dec. 10 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... (POC) products under the,Vantus brand. Unveiling of the ... 54th Annual Convention of the American Association of Equine,Practitioners ...
... HONOLULU, Dec. 10 Hoana Medical announced today that ... at the Institute for Healthcare Improvement (IHI) premier event ... leaders in hospital,safety. , ... conjunction with the,IHI event, to introduce its LifeGurney system, ...
... prostate cancer patients with drugs that block hormonal activity ... from cardiovascular disease, according to a study led by ... report from members of the same study team found ... risk of diabetes and heart disease, the current study ...
... A group of nutritionists from Extenso, the Universit de ... chefs from the Institut de tourisme et d,htellerie du ... and early childhood centres. The goal is to help ... for kids. , The nutrition team will provide its ...
... Ga., Dec. 10 Joe Jurevicius, Tom Brady, ... few months the list,of top professional football players ... read as a who,s who of the National ... infections is healthcare facilities,where athletes are undergoing surgeries, ...
Cached Medicine News:Health News:Obesity among state's low-income teens nearly triple that of more affluent peers 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 2Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 3Health News:ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention 4Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 2Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 3Health News:Hoana Medical to Present at the National Forum on Quality Improvement in Health Care 4Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 2Health News:Hormone therapy for prostate cancer does not appear to increase cardiac deaths 3Health News:New partnership to foster healthier food habits in early childhood 2Health News:Staph Infections Hit Professional Football Hard 2Health News:Staph Infections Hit Professional Football Hard 3
Pocket-sized instrument with direct illumination. Avaliable in black, green or blue....
Provides 30% more illumination, high light output for true tissue. Wide-angle viewing lens, sealed system for pneumatic otoscopy....
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... delivers power and reliability with proprietary ... Diode side-pumping technology drives 2.5 W ... Spectra system, and active resonator temperature ... system reliability from your first treatment ...
Medicine Products: